Search

Sana Biotechnology Inc

Fermé

SecteurSoins de santé

3.19 1.92

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.1

Max

3.24

Chiffres clés

By Trading Economics

Revenu

-16M

-64M

BPA

-0.13

Employés

142

EBITDA

-17M

-61M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+155.59% upside

Dividendes

By Acuity

Prochains Résultats

4 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

268M

1.2B

Ouverture précédente

1.27

Clôture précédente

3.19

Sentiment de l'Actualité

By Acuity

25%

75%

34 / 339 Classement par Healthcare

Sana Biotechnology Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 sept. 2026, 20:03 UTC

Correlated Moves

Sana Biotechnology Inc. is trading higher today, benefiting from strong market activity alongside Recursion Pharmaceuticals Inc. despite remaining below its 20-day moving average.

11 sept. 2026, 23:46 UTC

Sana Biotechnology Inc. shares are higher in after-market hours, despite no specific news identified. Broader market context includes recent U.S. inflation data.

10 sept. 2026, 20:07 UTC

News
Correlated Moves

Sana Biotechnology Inc shares are lower amid a broader biotechnology sector decline, influenced by rising Treasury yields and inflation concerns affecting market sentiment.

9 sept. 2026, 23:01 UTC

Sana Biotechnology Inc. shares are higher in after-market hours, recovering from earlier declines amid unclear drivers for the price movement.

8 sept. 2026, 20:03 UTC

News

Sana Biotechnology shares are declining despite a report on diabetes treatment advancements and a $25 million investment from Mayo Clinic.

4 sept. 2026, 20:07 UTC

Sana Biotechnology Inc shares are lower amid broader market pressures following a strong jobs report, with no specific company news identified.

2 sept. 2026, 20:08 UTC

Social Media
News

Sana Biotechnology Inc is advancing today amid gains in the Biotechnology sector and upcoming investor conferences focused on engineered cell therapies.

31 août 2026, 20:07 UTC

Sana Biotechnology Inc. shares decline today, continuing a trend since Friday's close, amid broader market pressures from rising interest rate expectations.

28 août 2026, 23:56 UTC

Sana Biotechnology Inc. shares advanced modestly higher in after-market trading, remaining near the upper end of their one-month range.

27 août 2026, 23:02 UTC

Sana Biotechnology shares declined in after-market trading, reflecting a notable drop since Thursday's close, despite earlier gains earlier in the session.

26 août 2026, 19:46 UTC

Sana Biotechnology Inc shares are higher today, trading near the upper end of their one-month range and above the 20-day moving average.

25 août 2026, 23:16 UTC

Sana Biotechnology Inc shares are lower in after-market hours. Market sentiment was affected by a sharp decline in crude oil prices.

24 août 2026, 19:36 UTC

Correlated Moves

Sana Biotechnology Inc's shares are lower today, reflecting broader declines in the biotech sector, including a drop in the ARK Genomic Revolution ETF.

21 août 2026, 23:36 UTC

Sana Biotechnology Inc. shares moved lower in after-market trading, despite resilience in major stocks like Tesla and UnitedHealth. The price remains above its 20-day moving average.

20 août 2026, 23:01 UTC

Sana Biotechnology Inc. shares are higher in after-hours trading, driven by gains in the Biotechnology sub-sector and remaining above its 20-day moving average.

19 août 2026, 23:06 UTC

Sana Biotechnology Inc shares are lower in after-market hours, following a notable decline from earlier highs. No specific news was identified to explain the move.

18 août 2026, 19:46 UTC

Sana Biotechnology Inc. shares are lower today, reflecting a decline since Monday amid rising Treasury yields and ongoing inflation concerns.

17 août 2026, 23:46 UTC

Sana Biotechnology Inc shares are slightly higher in after-market hours. No specific news was identified to explain the movement.

14 août 2026, 20:06 UTC

News

Sana Biotechnology shares declined amid mixed analyst ratings and broader market challenges, with BofA lowering its price target to $6.00 from $7.00.

13 août 2026, 19:36 UTC

Sana Biotechnology Inc shares are lower today, continuing a decline since Wednesday. The price remains above its 20-day moving average.

12 août 2026, 23:46 UTC

Sana Biotechnology Inc shares are lower in after-market hours, with no specific news identified to explain the price movement.

11 août 2026, 19:31 UTC

News

Sana Biotechnology shares are higher following Q2 results showing an adjusted EPS of -$0.13, exceeding estimates, and a $25 million investment from Mayo Clinic.

10 août 2026, 23:01 UTC

News

Sana Biotechnology Inc shares are lower in after-market hours following a second-quarter loss of $63.6 million, despite an adjusted EPS that exceeded expectations.

7 août 2026, 19:56 UTC

Sana Biotechnology Inc. shares are higher, supported by broader market dynamics following a disappointing jobs report easing interest rate concerns.

5 août 2026, 19:56 UTC

Sana Biotechnology Inc. is trading higher during Wednesday's session, having peaked earlier before pulling back slightly while remaining above its 20-day moving average.

4 août 2026, 20:05 UTC

Sana Biotechnology Inc shares are higher, reflecting strong performance amid a decline in crude oil prices, which may ease inflationary pressures.

3 août 2026, 19:46 UTC

Sana Biotechnology Inc is higher today, benefiting from a broader market rally, particularly in technology, despite earlier session pullbacks.

31 juil. 2026, 23:06 UTC

Sana Biotechnology Inc shares are lower in after-market hours, retracing from earlier gains. Broader market trends show mixed sentiment among major tech firms.

30 juil. 2026, 19:29 UTC

Sana Biotechnology Inc shares are higher today, recovering from earlier lows. The stock has shown an upward trend since Wednesday's close.

29 juil. 2026, 23:36 UTC

Sana Biotechnology Inc shares are higher in after-market hours, reflecting a slight increase since Wednesday's close amid routine market activity and broader volatility.

Comparaison

Variation de prix

Sana Biotechnology Inc prévision

Objectif de Prix

By TipRanks

155.59% hausse

Prévisions sur 12 Mois

Moyen 8 USD  155.59%

Haut 12 USD

Bas 6 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

5

Achat

0

Maintien

0

Vente

Sentiment

By Acuity

34 / 339Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
help-icon Live chat